Innovation’s Kevetrin Shows Promising Results in Trial for Late-stage Ovarian Cancer

Innovation’s Kevetrin Shows Promising Results in Trial for Late-stage Ovarian Cancer
A Phase 2a trial testing Innovation Pharmaceuticals’ p53 modulator Kevetrin as a treatment for late-stage ovarian cancer has been completed, the company announced. The study showed positive anti-cancer results, supporting the development of an oral formulation of the investigational therapy. Kevetrin is a small-molecule activator of p53, a key protein across human cancer. The p53 gene is a tumor suppressor  a type of gene that stops tumor growth. Mutations in the p53 gene, which prevent the p53 protein from exerting its anti-cancer effects, have been linked to human tumors more than any other gene in the genome. By binding to p53, Kevetrin can lead to the death of cancer cells. The study (NCT03042702) evaluated Kevetrin's ability to modulate p53 in late stage, platinum-resistant/refractory ovarian cancer patients. Modulation of p53 was demonstrated in the analysis of the first ovarian cancer patients treated with the lowest dose. Patients receiving higher levels of the therapy also received more frequent dosing — three times a week  which was followed by standard-of-care treatment after the trial's conclusion. The data also showed that Kevetrin alters the level of genes that contro
Subscribe or to access all post and page content.